World Health Organization recognizes new antifungal class
Scynexis, Inc., a biotechnology company delivering innovative therapies for difficult-to-treat and often lifethreatening infections, recently announced that the
World Health Organization’s (WHO) International Nonproprietary Name (INN) group has assigned the generic name “ibrexafungerp” for its lead candidate SCY-078, the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family.
Scynexis is developing ibrexafungerp for the treatment of multiple serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections.
The INN system was established to facilitate the identification of pharmaceutical substances or active pharmaceutical ingredients in a unique, globally-recognized manner. Obtaining a non-proprietary, or generic, name is a required step in bringing a new drug to market. Generic names of pharmacologicallyrelated substances demonstrate their relationship by using a common stem, allowing medical practitioners and pharmacists to recognize substances having similar pharmacological activity. This is important for the clear identification, safe prescription and dispensing of medicines to patients.